IDH3B | bioCADDIE Data Discovery Index
Mountain View
biomedical and healthCAre Data Discovery Index Ecosystem
help Advanced Search
Displaying 9 of 9 results for "IDH3B"
i
  1. Crystal structure of NAD dependent isocitrate dehydrogenase from Acidithiobacillus thiooxidans PDB

    ID: PDB:2D4V

    Description: isocitrate dehydrogenase

  2. Crystal structure of isocitrate dehydrogenase from Aeropyrum pernix PDB

    ID: PDB:1V94

    Description: isocitrate dehydrogenase(E.C.1.1.1.42)

  3. Genome-wide maps of the total and lysine methylated enriched pools of peroxisome proliferating activated receptor gamma (pparg) co-activator 1 alpha (... ArrayExpress

    ID: E-GEOD-57852

    Description: f ppargc1a occupation in hepatic cells for Sirt5, Idh3b, Pfkl, and Hmox2 strongly corresponds with the enrichment of enhancer -associated RNAs. Examination of the genomic disttribution of the total pool of ppargc1a and the lysine methylated (K779me) enriched pool of ppargc1a in mouse Hepa1-6 hepatoma cells....

  4. Genotyping by array of patients with Autosomal Recessive Retinitis Pigmentosa using targeted resequencing ArrayExpress

    ID: E-MTAB-786

    Description: daries of 16 arRP genes (CERKL, CNGA1, CRB1, EYS, IDH3B, LRAT, MERTK, NR2E3, PDE6B, PRCD, PROM1, RGR, RHO, RLBP1,RPE65 and TULP1) were resequenced using Affymetrix microarrays in 102 Spanish s with clinical diagnosis of arRP. All the detected variations were confirmed by direct sequencing and potential pathogenicity was assessed by functional predictions and frequency in controls....

  5. Genome-wide maps of the total and lysine methylated enriched pools of peroxisome proliferating activated receptor gamma (pparg) co-activator 1 alpha (... BioProject

    ID: PRJNA248238

    Keywords: Epigenomics

    Access Type: download

    dataset.description: f ppargc1a occupation in hepatic cells for Sirt5, Idh3b, Pfkl, and Hmox2 strongly corresponds with the enrichment of enhancer -associated RNAs. Overall design: Examination of the genomic disttribution of the total pool of ppargc1a and the lysine methylated (K779me) enriched pool of ppargc1a in mouse Hepa1-6 hepatoma cells....
  6. IDH3B_PIG UniProt:Swiss-Prot

    ID: P56472

    Description: Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial

  7. IDH3B_RAT UniProt:Swiss-Prot

    ID: Q68FX0

    Description: Mitochondrion Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Magnesium or ma...

  8. Genotyping by array of patients with Autosomal Recessive Retinitis Pigmentosa using targeted resequencing OmicsDI

    ID: E-MTAB-786

    Date Released: 01-25-2012

    Description: daries of 16 arRP genes (CERKL, CNGA1, CRB1, EYS, IDH3B, LRAT, MERTK, NR2E3, PDE6B, PRCD, PROM1, RGR, RHO, RLBP1,RPE65 and TULP1) were resequenced using Affymetrix microarrays in 102 Spanish s with clinical diagnosis of arRP. All the detected variations were confirmed by direct sequencing and potential pathogenicity was assessed by functional predictions and frequency in controls....

  9. Homo sapiens : Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse. BioProject

    ID: PRJNA305214

    Keywords: exome

    Access Type: download

    dataset.description: eciated genes such as MLL3, NSD1, FAT1, FAT4, and IDH3B. Mutations in 9 genes were observed in the relapse-specific phase. DNMT3A mutations are the most stable mutations, and this DNMT3A-transformed clone can be present even in morphologic complete remissions. Of note, all AML matched trio samples shared at least 1 genomic alteration at diagnosis and relapse, suggesting common ancestral clones. Two types of clonal evolution occur at relapse: either the founder clone recurs or a subclone of the founder clone escapes from induction chemotherapy and expands at relapse by acquiring new mutations. Relapse-specific mutations displayed an increase in transversions. Functional assays demonstrated that both MLL3 and FAT1 exert tumor-suppressor activity in the FLT3-ITD subtype. An inhibitor of XPO1 synergized with standard AML induction chemotherapy to inhibit FLT3-ITD growth. This study clearly shows that FLT3-ITD AML requires additional driver genetic alterations in addition to FLT3-ITD alone....

Displaying 9 of 9 results for "IDH3B"